Venetoclax is a selective BCL2 inhibitor that has gained prominence in the treatment of lymphoid and myeloid malignancies, and its use has become the standard of care for patients with AML ineligible for intensive chemotherapy, being active in all spectra of risk groups, inducing a complete hematological remission with complete (CHR) or incomplete blood count recovery (Cri) in more than 65% of patients [25,26,27,28,29,30]. This evidence concerns the gene BCL2 and cancer.